Breast Cancer
News
Tamoxifen benefit in lower-risk breast cancer varies by intrinsic subtype
Among postmenopausal patients with node-negative, ER-positive breast cancer, significant benefit of adjuvant tamoxifen over no endocrine therapy...
News
Aspirin interacts with epigenetics to influence breast cancer mortality
Prediagnosis aspirin use appears to influence breast cancer mortality in women with certain epigenetic changes to particular breast cancer–related...
Article
Genomic Medicine and Genetic Counseling in the Department of Veterans Affairs and Department of Defense
News
High EPclin score equals chemo benefit in ER+/HER2– breast cancer
Women with high EPclin scores would be likely to have an absolute benefit from chemotherapy added to endocrine therapy, a mathematical model...
News
CVD risk after breast cancer: Adipose distribution trumps BMI
The more fat that breast cancer survivors had in the visceral compartment or intramuscular compartment, the higher their CVD risk, regardless of...
News
Cost a factor in breast cancer treatment decisions
Though cost was a significant factor in decisions about surgical options, more than three-quarters of women said they never discussed costs with...
News
ctDNA may predict relapse risk in early breast cancer
Circulating tumor DNA was associated with a significant risk for relapse in women treated for early primary breast cancers.
News
Results support first-line T-DM1 in HER2+ breast cancer
A phase 3 trial showed similar overall survival times in patients who received trastuzumab emtansine (T-DM1), T-DM1 plus pertuzumab, or...
News
Depression, anxiety among elderly breast cancer survivors linked to increased opioid use, death
Among 10,452 breast cancer survivors prescribed adjuvant endocrine therapy, those with mental health comorbidities were 33% more likely to use...
News
Standard chemotherapy remains superior in early breast cancer
The 10-year recurrence-free survival rates were 56% with standard chemotherapy versus 50% with capecitabine in a randomized noninferiority trial...